Exscientia products

Exscientia - Clinical Trial Drug

In the landmark study, it was demonstrated for the first time that our functional precision-oncology platform can improve patient outcome in a prospective interventional trial.

Exscientia - Precision Target Medicine

Target selection is key to creating success in drug discovery. Selecting each target is a significant decision and the future success of any molecule will depend on that initial decision.

Exscientia - Peripherally-Restricted and Selective Antagonist Drug

EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell activation.